7 results about "Fasudil" patented technology

A method for treating patients with NOTCH3 mutations using a rho kinase inhibitor has been disclosed. Abnormal NOTCH3 signaling is a pathological factor in cerebral small vessel diseases, including CADASIL. A preferred embodiment relates to treating patients orally with the rho kinase inhibitor fasudil or its active metabolite hydroxyfasudil.

This invention provides the application of fasudil in the preparation of a drug for the prevention and / or treatment of neuropathic pain following spinal cord injury, relating to the field of pharmaceutical technology. Experimental data show that fasudil can significantly improve the pain behavior of rats with spinal cord injury, and its mechanism of action may be related to the inhibition of Rho / ROCK signaling pathway activation. Further studies have found that fasudil intervention during the acute phase of spinal cord injury can produce a relatively long-lasting analgesic effect, showing promising application prospects.

Disclosed herein are formulations of fasudil and methods for using the same to treat neurological conditions such as ALS.

A method of treating a patient having a NOTCH3 mutation with an rho kinase inhibitor is disclosed. Abnormal NOTCH3 signaling is a pathological participant in small vascular cerebrovascular diseases, including CADASIL. A preferred aspect relates to the treatment of a patient in an oral manner with said rho kinase inhibitor, i.e., fasudil, or an active metabolite thereof, i.e., hydroxyfasudil.

An oral pharmaceutical composition is provided that can comprise a rho kinase inhibitor, for example, fasudil, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, or a metabolite thereof, or any combination thereof, the rho kinase inhibitor having a bitter taste; and an ion exchange resin. The ion exchange resin can partially or fully mask the bitter taste of the rho kinase inhibitor, making the composition more palatable. The composition can comprise a solid dosage form, and / or a liquid dosage form. The solid dosage form can comprise a powder, granules, a tablet, or a capsule, or any combination thereof. The composition can be present, for example, in a unit dose, in an amount sufficient to treat a neurodegenerative disease. A method of treating the neurodegenerative disease with the oral pharmaceutical composition is provided. The method can ameliorate a symptom of a neurodegenerative disease.

The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fasudil. Fasudil is administered at a dose of 60-240 mg / day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.